148,688 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Eversept Partners LP

Eversept Partners LP purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 148,688 shares of the medical device company's stock, valued at approximately $11,563,000. DexCom comprises approximately 1.0% of Eversept Partners LP's portfolio, making the stock its 19th biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of DexCom by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares during the last quarter. Jennison Associates LLC boosted its stake in DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after buying an additional 710,858 shares during the period. Norges Bank purchased a new position in DexCom during the fourth quarter worth about $385,367,000. Charles Schwab Investment Management Inc. increased its position in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after acquiring an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership raised its stake in shares of DexCom by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after acquiring an additional 201,181 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and increased their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $99.00.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 over the last ninety days. Insiders own 0.32% of the company's stock.

DexCom Stock Up 1.2 %

Shares of DXCM traded up $0.88 during mid-day trading on Friday, reaching $71.66. The company's stock had a trading volume of 2,857,981 shares, compared to its average volume of 4,237,076. The company's 50 day moving average is $73.46 and its 200 day moving average is $76.61. The stock has a market cap of $28.10 billion, a PE ratio of 50.11, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $138.81. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.